Our result suggests that MELK may be a pan-cancer oncogenic kinase and a promising selective therapeutic target for multiple cancer types including uterine corpus endometrial carcinoma, bladder urothelial carcinoma, lung cancer, liver cancer, and kidney cancers. Here, MELK is linked to bladder transitional cell carcinoma.